Fusion Pharmaceuticals Announces Research Collaboration with 48Hour Discovery to Develop Peptide-Based Radiopharmaceuticals

January 11, 2022 | | Press Releases |

Original Post from: https://ir.fusionpharma.com/2022-01-11-Fusion-Pharmaceuticals-Announces-Research-Collaboration-with-48Hour-Discovery-to-Develop-Peptide-Based-Radiopharmaceuticals HAMILTON, Ontario and BOSTON, Jan. 11, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision...

Read More

48Hour Discovery and RayzeBio Announce Strategic Research Collaboration

July 12, 2021 | | Press Releases |

Link to Business Wire article: https://www.businesswire.com/news/home/20210712005120/en/48Hour-Discovery-and-RayzeBio-Announce-Strategic-Research-Collaboration-to-Discover-Develop-Novel-Peptide-Based-Radiopharmaceuticals Edmonton, AB Canada, & San Diego, CA, USA 48Hour Discovery Inc and RayzeBio today announced the companies have entered a strategic research collaboration...

Read More